Lv11
90 积分 2023-04-06 加入
RNAi-based drug design: considerations and future directions
9小时前
已完结
Abstract 4393: Development of an anti-CD171 (L1CAM) antibody-drug conjugate with high avidity and strong activity in resistant tumor models
5天前
已关闭
Outlook for medicines development and use in 2025
3个月前
已完结
Cyclic peptide drugs approved in the last two decades (2001–2021)
6个月前
已完结
Abstract 6304: Preclinical development of a next generation antibody drug conjugate (ADC) targeting B7-H3 for treatment of solid tumors
10个月前
已关闭
A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors
10个月前
已完结
皖公网安备34019202002308
